Thursday 10 September 2026

One To Watch

Avalon Ventures


Want to Update your Company's Profile?


Latest Avalon Ventures News

TwoStep gains series A backing and FDA clearance to trial multi-target cancer conjugate
10 September 2026
Bio-Thera, Avalon strike MENA deal for proposed Keytruda biosimilar
9 February 2026
Pan Cancer T secures 10 million euros to develop TNBC therapy
8 December 2025
Arialys launches with $58 million for autoimmune neuropsychiatric diseases
15 September 2023
More Avalon Ventures news >


Today's issue

US generic and biosimilar meds save $496B in just 1 year
Generics
US generic and biosimilar meds save $496B in just 1 year
10 September 2026
Biotechnology
NICE backs Darzalex-based quadruplet for newly-diagnosed myeloma, J&J's second blood cancer win in a week
10 September 2026
Biotechnology
Tyra Biosciences Phase II SURF302 results support LG IR NMIBC with dabogratinib
10 September 2026
Biotechnology
Evommune's EVO756 misses primary endpoint in atopic dermatitis Phase IIb
10 September 2026
Biotechnology
FDA accepts Roche’s Enspryng sBLA for MOGAD
10 September 2026
Biotechnology
Solstice Oncology launches with $225 million to advance neoadjuvant CTLA-4 antibody
10 September 2026
Biotechnology
Alchemab Therapeutics expands leadership team
10 September 2026




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze